Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is a clinical-stage biopharmaceutical company with a strong pipeline and solid financials, poised for success and growth. The company's lead candidate, pemvidutide, has the potential to address a significant unmet need in multiple liver diseases and has shown promise in early clinical trials. With a well-capitalized balance sheet and upcoming catalysts in the form of phase 2 and phase 3 trials, Altimmune is well-positioned for future success.

Bears say

Altimmune is facing multiple challenges as their drug pemvidutide faces further development and trials, and success in these trials is critical for the company's future success and stock performance. The company's near-term value-creation opportunity for pemvidutide may be limited, as there are other more advanced candidates in the market, and delays in development could harm the company's prospects. Additionally, the company may face competition from other drugs in the market and may need to form partnerships to complete clinical development and commercial launches, which could affect their profitability. Altimmune remains a buy due to its potential risk/reward opportunity, with its current low market valuation and upcoming catalysts including topline data from the Ph2 RECLAIM alcohol use disorder trial and the potential for a breakthrough therapy designation. However, the recent dilution and downgraded price target highlight concerns about potential further capital requirements and delays in trials.

Altimmune (ALT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.